

Special Issue

Advanced Research in Molecular Imaging of Immunity and Inflammation

Message from the Guest Editors

Molecular therapies addressing specific targets are increasingly being incorporated in multimodal treatment regimens, especially in the field of oncology but also in other areas of medicine. Moreover, immunity is evolving as a central hallmark of disease development. Similarly, modulating the immune response has shown major impact on cancer, cardiovascular disease and rheumatologic diseases. While the ‘-omics’ approaches offer comprehensive snapshots of dedicated biomarkers, imaging can take this information to another level, following the activity of these markers in space and over time. Thus, the demand for highly specific imaging of molecular and cellular processes remains. Enabled by further advances in instrumentation, tracer chemistry and preclinical modelling, molecular imaging is an important driver of biomedical research. In this Special Issue of *Biomedicines*, we want to give an overview of recent research highlights across the broad field of Molecular Imaging. Submissions from all fields across Molecular Imaging are encouraged, including imaging chemistry, methodological advances and applications in basic and translational research.

Guest Editors

Prof. Dr. Moritz Wildgruber

Department of Radiology, University Hospital, LMU Munich, 81377 München, Germany

Dr. Michel Eisenblätter

King's College, University of Freiburg, London, UK

Deadline for manuscript submissions

closed (30 June 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/51085

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).